Pak appoints new prosecutor in Mumbai attack case

September 13, 2013

Mumbai_attackBishkek, Sep 13: Pakistan has informed India that it has appointed a new prosecutor to probe the 2008 Mumbai terror attack and will send a Judicial Commission to the country on September 23 to cross-examine witnesses in the case, meeting India's demand for progress in the investigations.

External Affairs Minister Salman Khurshid today said he was told about Pakistan's decision during an informal chat he had with Sartaj Aziz, the advisor to Pakistan Prime Minister on Foreign Affairs, here in the capital of Kyrgyzstan last night.

"We had an informal chat. We had a good chat. We have been together here," he said.Aziz and Khurshid, who are here for the Shanghai Cooperation Organisation (SCO) Summit, shared the same table over dinner.

Talking to reporters, Khurshid said that he was informed by Pakistan about a new prosecutor been appointed in the Mumbai attacks case.

"One emphasis that we have legitimately given is the public sentiment on the slow progress of the Mumbai incident. We want accountability for the Mumbai incident," he said.

"We have been told that a Judicial Commission will come to India on September 23 to cross examine witness in connection with 26/11. Another thing is that a prosecutor has been appointed."

The appointment of a new prosecutor to handle the 26/11 Mumbai attack case came as the previous prosecutor Chaudhry Zulfizar Ali was shot dead by unidentified gunmen in May.

Pakistan's decisions came as India has been demanding action against perpetrators of the Mumbai attacks and steps to curb activities of anti-India militant leaders like Jamaat-ud-Dawah chief Hafiz Saeed.

On whether roadblocks for discussion between Prime Ministers of the two countries later this month in New York have been removed, Khurshid said, "We told him that in view of the wish of the people for positive talks, there has to be a conducive atmosphere. Whenever high-level talk process is on, atmosphere should be good."

"If there is a lack in atmospherics, there is a need to correct things to proceed. But if things are not sorted then there difficulties are faced," he said.

Pakistan has been pushing for a meeting between Prime Minister Nawaz Sharif and his Indian counterpart Manmohan Singh on the margins of the UN General Assembly in New York later this month. India has been non-committal on the meeting.

Relations between the two countries soured after five Indian soldiers were killed in an attack by Pakistani troops on the Indian side of the LoC on August 6. Both sides have accused each other of violating the truce along the LoC.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
January 2,2020

Perambalur, Jan 2: Veteran Tamil writer Nellai Kannan was arrested in Perambalur for criticizing Prime Minister Narendra Modi and Home Minister Amit Shah during a protest against Citizenship (Amendment) Act.

The Tirunelveli Police had registered the FIR against the writer for the speech delivered at a meeting, which was called by the Social Democratic Party of India on December 29 last year.

The police have booked him on the basis of multiple complaints filed by BJP leaders.

Kannan has been booked under Sections 504, 505(1) and 505(2) of the Indian Penal Code.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
April 19,2020

Shimla, Apr 19: A man, who had recovered from the novel coronavirus, was again found suffering from the infection in Himachal Pradesh, officials said.

The man, a Tablighi Jamaat member, tested positive for the infection on Saturday within a week of his two reports coming out negative, they said.

Residents of different places in Mandi district, the man along with two other Jamaatis had been staying in a mosque of Nakroh village in Una'a Amb tehsil and all tested positive on April 2.

They were admitted to Tanda's Dr. Rajendra Prasad Government Medical College (RPGMC) in Kangra district on April 3.

As per the available information, they had tested negative for the first time on April 10 and they were declared as cured as per protocol after they tested negative for the second time on April 12.

Subsequently they had been discharged from the RPGMC and were kept in institutional quarantine.

However, with the man again testing positive, the total number of active cases in the hill state has increased to 23 out of the total 40 positive cases.

Four persons have been shifted to a private hospital outside the state. Eleven have recovered while two others have died.

A total of 16 confirmed cases were found in Una and health department statistics now shows 14 active cases and two cured.

Officials said 11 patients — three each from Chamba, Kangra, and Solan districts and two from Una district — have recovered.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
June 30,2020

Hyderabad, Jun 30: Hyderabad-based Bharat Biotech announced that it has successfully developed Covaxin, India's first vaccine candidate for Covid-19, in collaboration with the Indian Council of Medical Research (ICMR) and National Institute of Virology (NIV).

The Drug Controller General of India - CDSCO, Ministry of Health & Family Welfare granted permission to initiate Phase I & II Human clinical trials after the company submitted results generated from preclinical studies, demonstrating safety and immune response. Human clinical trials are scheduled to start across India in July 2020.

The SARS-CoV-2 strain was isolated in NIV, Pune and transferred to Bharat Biotech.

The indigenous, inactivated vaccine developed and manufactured in the company's Bio-Safety Level 3 (BSL-3) High Containment facility located in Genome Valley, Hyderabad.

Announcing the vaccine development milestone, Dr Krishna Ella, Chairman and Managing Director said: "We are proud to announce COVAXIN, India's first indigenous vaccine against COVID-19. The collaboration with ICMR and NIV was instrumental in the development of this vaccine."

Dr Ella added, "The proactive support and guidance from CDSCO has enabled approvals to this project. Our R&D and Manufacturing teams worked tirelessly to deploy our proprietary technologies towards this platform."
Expedited through national regulatory protocols, the company accelerated its objective in completing the comprehensive pre-clinical studies. Results from these studies have been promising and show extensive safety and effective immune responses.

Speaking about Bharat Biotech's prowess, Suchitra Ella, Joint Managing Director said, "Our ongoing research and expertise in forecasting epidemics has enabled us to successfully manufacture a vaccine for the H1N1 pandemic."
"Continuing our focus on creating the only BSL-3 containment facilities for manufacturing and testing in India, Bharat Biotech is committed to advancing vaccine development as a matter of national importance to demonstrate India's strength in handling future pandemics," she added.

Bharat Biotech's track record in developing vero cell culture platform technologies has been proven in several vaccines for Polio, Rabies, Rotavirus, Japanese Encephalitis, Chikungunya and Zika.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.